This is a working overview of peptide analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
=== Eriq: The Bum Rapper === First aired 19 April 2009 Mayhem Miller helps Eriq's ex-girlfriend Linda, by putting him in the ring with MMA champion Jon "Man of Faith" Murphy. She is the first female victim to appear on Bully Beatdown. Eriq taps out five times in the first round and quits very shortly into the second round, claiming his shoulder popped out. The on-site doctor found no such injury, and Linda states that Eriq frequently uses a shoulder injury claim when he fears losing a fight. The information Mayhem provided from the doctor and the statement from Linda leave the audience knowing the high likelihood that Eriq 'punked out' with a fake injury. She won $10,000.
FGFR1 oncogene partner 2 (FGFR1OP2) is a protein that in humans is encoded by the gene FGFR1OP2. It was identified in a study on myeloproliferative syndrome (EMS). The study aimed to identify the partner genes to the fibroblast growth factor receptor 1 (FGFR1) involved in the syndrome. Using the 5'-RACE PCR technique, FGFR1OP2 was identified as a novel gene with no known function.
=== Knight Bachelor === Alan Ayckbourn, , Playwright. For services to The Theatre. Jack Mervyn Frank Baer. For services to the Art Trade. Nicholas Brian Baker, , Member of Parliament for Dorset North. For political service. Alec Victor Bedser, . For services to Cricket. Thomas Leon Blundell, . For services to the Biotechnology and Biological Sciences Research Council and to Scientific Research. Alan Peter Budd, Chief Economic Adviser to Her Majesty's Treasury and Head, Government Economic Service. Peter John Davis, Chairman, National Advisory Council for Education and Training Targets. For services to Training and to Industry. Simon James Day. For political and public service. Geoffrey James Dear, , Her Majesty's Inspector of Constabulary. For services to the Police. Richard Charles Hastings Eyre, , Artistic Director, Royal National Theatre. For services to Drama. David Harrison, , Master, Selwyn College, University of Cambridge. For services to Education and to Nuclear Safety. John Smith Harvie, . For political and public service. Robert Baynes Horton, Chairman, Railtrack plc. For services to the Railway Industry. Gordon Minto Hourston, Chairman, Armed Forces' Pay Review Body. For services to the Armed Forces and to Industry. Michael Nicholas Howard Jenkins, , Chairman, Futures and Options Association and the London Clearing House. For services to the Finance Industry. John Martin Kirby Laing, , Chairman, John Laing plc. For services to the Construction Industry. James Paul McCartney, , Musician. For services to Music. Professor Samuel Roy Meadow.
Sources: en.wikipedia.org
These models have a prominent bonnet scoop. At about the same time a all-wheel-drive model was introduced in Japan, either with a 1.6-litre petrol or the Isuzu turbo-diesel. The 4WD cars can be easily identified by having been equipped with the federalized front (but not rear) bumper, including side marker lights. The rare North American ES model came with the Miata (NA)'s 1.8-litre twin-cam engine (though the internals were not entirely the same), all-wheel disc brakes, and dual stabilizer bars. The same car went on sale in Australia in the second half of 1994 with a fully featured BP-ZE engine. The Protegé became classified as a "compact car" for the 1995 model year in North America. A version with Mazdaspeed accessories was released in Japan and Philippines. It came equipped with Mazdaspeed wrap around bodykit, Mazdaspeed rear spoiler, Momo steering wheel, 15-inch Rota Astral wheels wrapped in 195/55R15 Bridgestone Potenza RE01 tires, Mazdaspeed strut tower bar, Eibach springs, gas-charged shock absorbers, swaybars and Mazdaspeed exhaust made by Yumex. The Familia/Protegé/323 was facelifted in October 1996, with a newer somewhat calmer style. This generation was discontinued in 1998 in most markets, but continued to be available in some markets until 1999 or 2000. For example, the 3-door hatchback was available in Europe until October 2000.
=== Femarelle Unstoppable === Femarelle Unstoppable is designed for postmenopausal women, with a focus on bone health, muscle function, and overall wellbeing during later stages of menopause. The formulation contains DT56a, calcium, vitamin D3, biotin, and riboflavin (vitamin B2).
==== Nibble ==== A measure of quantity of data or information, the "nibble" (sometimes spelled "nybble" or "nybl") is normally equal to 4 bits, or one half of the common 8-bit byte. The nibble is used to describe the amount of memory used to store a digit of a number stored in binary-coded decimal format, or to represent a single hexadecimal digit. Less commonly, 'nibble' may be used for any contiguous portion of a byte of specified length, e.g. "6-bit nibble"; this usage is most likely to be encountered in connection with a hardware architecture in which the word length is not a multiple of 8, such as older 36-bit minicomputers.
=== Commonly occluded sites === Arterial emboli often occur in the legs and feet. Some may occur in the brain, causing a stroke, or in the heart, causing a heart attack. Less common sites include the kidneys, intestines, and eyes.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.